TD Cowen Cuts Boston Scientific (NYSE:BSX) Price Target to $56.00

Boston Scientific (NYSE:BSX) had its target price decreased by equities researchers at TD Cowen from $61.00 to $56.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. TD Cowen’s price objective would suggest a potential upside of 23.75% from the stock’s current price.

Several other equities analysts have also recently commented on the stock. Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. UBS Group reissued a “buy” rating and set a $74.00 target price (down from $95.00) on shares of Boston Scientific in a research report on Tuesday. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a research report on Wednesday. Truist Financial cut their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Royal Bank Of Canada lowered their price target on shares of Boston Scientific from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $71.96.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded down $0.79 during midday trading on Thursday, hitting $45.25. The company’s stock had a trading volume of 7,383,895 shares, compared to its average volume of 18,244,801. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock’s 50 day simple moving average is $46.57 and its 200 day simple moving average is $62.73. The stock has a market capitalization of $67.26 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 0.88 and a beta of 0.58. Boston Scientific has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.37 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts anticipate that Boston Scientific will post 3.35 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In other news, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by insiders.

Institutional Trading of Boston Scientific

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $26,000. Main Street Financial Solutions LLC increased its holdings in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its position in Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after purchasing an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its holdings in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after buying an additional 2,556 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q2 results exceeded expectations: Boston Scientific reported adjusted EPS of $0.86 versus the $0.83 consensus estimate, while revenue rose 7.5% year over year to $5.442 billion, above the $5.37 billion forecast. Cardiovascular sales increased 8.3%, with particularly strong growth in APAC and LACA. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: Growth and cost initiatives remain longer-term catalysts: Management highlighted broad portfolio growth, new product launches, cost savings from its restructuring program, FDA clearance for the TruSelect 2.6 Microcatheter, and the company’s investment in MiRus and its transcatheter aortic valve replacement business. The restructuring targets approximately $500 million in annual savings, although it may cost $700 million to $800 million through 2029. Boston Scientific Q2 earnings call highlights
• Neutral Sentiment: Sales outlook was raised, but profit expectations were reduced: Boston Scientific now expects full-year reported sales growth of approximately 5.5% to 6.5%, but cut adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41. Third-quarter EPS guidance of $0.80-$0.82 and revenue guidance of $5.2-$5.3 billion also trail consensus estimates of $0.84 and $5.4 billion, respectively. Boston Scientific trims annual profit forecast
• Negative Sentiment: Watchman and EP weakness is resetting expectations: Softer demand for the Watchman device, competitive pressure and weaker trends in EP are forcing management to take a more cautious view of growth. Analysts have responded by cutting valuation targets, including UBS’s reduction to $74 from $95, BTIG’s reduction to $60 from $65, and a fair-value cut to $72.25 from $75. BSX Q2 earnings call highlights WATCHMAN and EP pressure
• Negative Sentiment: Restructuring and recall add execution risk: The multi-year restructuring will involve headcount reductions and significant upfront costs, while a recall of the Rapid Refill Continuous Injection System creates an additional operational and reputational concern. Boston Scientific expects headcount reductions

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.